{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:45:11Z","timestamp":1793677511846,"version":"4.5.1"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41571-026-01131-4","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:34:39Z","timestamp":1771853679000},"page":"374-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Innovative approaches for lung cancer screening and interception"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-3477","authenticated-orcid":false,"given":"Jianjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-8338","authenticated-orcid":false,"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Salehi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhubo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-2157","authenticated-orcid":false,"given":"Torsten G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-8039","authenticated-orcid":false,"given":"Steven M.","family":"Dubinett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol. 20, 624\u2013639 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395\u2013409 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning, H. J. et al. Reduced lung-cancer mortality with volume ct screening in a randomized trial. N. Engl. J. Med. 382, 503\u2013513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-020-01131-w","volume":"124","author":"MS Hansen","year":"2021","unstructured":"Hansen, M. S., Licaj, I., Braaten, T., Lund, E. & Gram, I. T. The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study. Br. J. Cancer 124, 658\u2013662 (2021).","journal-title":"Br. J. Cancer"},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-2600(21)00210-1","volume":"9","author":"AL Potter","year":"2021","unstructured":"Potter, A. L., Bajaj, S. S. & Yang, C. J. The 2021 USPSTF lung cancer screening guidelines: a new frontier. Lancet Respir. Med. 9, 689\u2013691 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/S1470-2045(23)00104-3","volume":"24","author":"EL O\u2019Dowd","year":"2023","unstructured":"O\u2019Dowd, E. L. et al. Defining the road map to a UK national lung cancer screening programme. Lancet Oncol. 24, e207\u2013e218 (2023).","journal-title":"Lancet Oncol."},{"key":"1131_CR7","unstructured":"Lung Cancer: Screening (US Prevetive Services Task Force, 2010); https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening."},{"key":"1131_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3338-9","volume":"18","author":"J Li","year":"2018","unstructured":"Li, J., Chung, S., Wei, E. K. & Luft, H. S. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low. BMC Health Serv. Res. 18, 525 (2018).","journal-title":"BMC Health Serv. Res."},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jnci\/djaa170","volume":"113","author":"SA Fedewa","year":"2021","unstructured":"Fedewa, S. A. et al. State variation in low-dose computed tomography scanning for lung cancer screening in the United States. J. Natl Cancer Inst. 113, 1044\u20131052 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jacr.2022.12.022","volume":"20","author":"DR Hughes","year":"2023","unstructured":"Hughes, D. R. et al. Comparison of lung cancer screening eligibility and use between commercial, medicare, and medicare advantage enrollees. J. Am. Coll. Radiol. 20, 402\u2013410 (2023).","journal-title":"J. Am. Coll. Radiol."},{"key":"1131_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389958","volume":"43","author":"RU Osarogiagbon","year":"2023","unstructured":"Osarogiagbon, R. U., Yang, P. C. & Sequist, L. V. Expanding the reach and grasp of lung cancer screening. Am. Soc. Clin. Oncol. Educ. Book 43, e389958 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1131_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.21037\/tlcr-23-816","volume":"13","author":"N Triphuridet","year":"2024","unstructured":"Triphuridet, N., Nagasaka, M., Shum, E. & Ou, S. I. Race, age at diagnosis and histological characteristics of lung cancer in never-smokers (LCINS) and ever-smokers in low-dose computed tomography (LDCT) screening: a systematic review and meta-analysis. Transl. Lung Cancer Res. 13, 1047\u20131060 (2024).","journal-title":"Transl. Lung Cancer Res."},{"key":"1131_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1258\/jms.2012.012010","volume":"19","author":"PF Pinsky","year":"2012","unstructured":"Pinsky, P. F. & Berg, C. D. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J. Med. Screen. 19, 154\u2013156 (2012).","journal-title":"J. Med. Screen."},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","volume":"21","author":"J LoPiccolo","year":"2024","unstructured":"LoPiccolo, J., Gusev, A., Christiani, D. C. & J\u00e4nne, P. A. Lung cancer in patients who have never smoked \u2014 an emerging disease. Nat. Rev. Clin. Oncol. 21, 121\u2013146 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44321-024-00175-2","volume":"17","author":"CY Chen","year":"2025","unstructured":"Chen, C. Y. et al. The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications. EMBO Mol. Med. 17, 31\u201340 (2025).","journal-title":"EMBO Mol. Med."},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jtho.2023.06.014","volume":"18","author":"DC Lam","year":"2023","unstructured":"Lam, D. C. et al. Lung cancer screening in Asia: an expert consensus report. J. Thorac. Oncol. 18, 1303\u20131322 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"102706","DOI":"10.1016\/j.eclinm.2024.102706","volume":"74","author":"CH Chiu","year":"2024","unstructured":"Chiu, C. H. & Yang, P. C. Challenges of lung cancer control in Asia. EClinicalMedicine 74,\u00a0102706 (2024).","journal-title":"EClinicalMedicine"},{"key":"1131_CR18","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan https:\/\/www.hpa.gov.tw\/EngPages\/Index.aspx (2025)."},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2021.09.008","volume":"33","author":"JL Dickson","year":"2022","unstructured":"Dickson, J. L. et al. Hesitancy around low-dose CT screening for lung cancer. Ann. Oncol. 33, 34\u201341 (2022).","journal-title":"Ann. Oncol."},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/cancers17091499","volume":"17","author":"H Li","year":"2025","unstructured":"Li, H. et al. Lung cancer risk prediction in patients with persistent pulmonary nodules using the Brock model and Sybil model. Cancers 17, 1499 (2025).","journal-title":"Cancers"},{"key":"1131_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/M13-2771","volume":"160","author":"VA Moyer","year":"2014","unstructured":"Moyer, V. A. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 160, 330\u2013338 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1131_CR22","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","volume":"325","author":"AH Krist","year":"2021","unstructured":"Krist, A. H. et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 325, 962\u2013970 (2021).","journal-title":"JAMA"},{"key":"1131_CR23","unstructured":"Lung cancer screening guidelines. American Cancer Society https:\/\/www.cancer.org\/health-care-professionals\/american-cancer-society-prevention-early-detection-guidelines\/lung-cancer-screening-guidelines.html (2024)."},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"00026","DOI":"10.1183\/23120541.00026-2023","volume":"9","author":"B Ward","year":"2023","unstructured":"Ward, B. et al. Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union\u2019s new recommendations on lung cancer screening. ERJ Open Res. 9, 00026\u201302023 (2023).","journal-title":"ERJ Open Res."},{"key":"1131_CR25","unstructured":"Zdravstva, M. National program for screening and early detection of lung cancer 2020\u20132024. Ministry of Health, Republic of Croatia https:\/\/zdravlje.gov.hr\/UserDocsImages\/2019%20Programi%20i%20projekti\/NACIONALNI%20PROGRAM%20PREVENCIJE%20RAKA%20PLU%C4%86A.pdf (2022)."},{"key":"1131_CR26","unstructured":"Screening for lung cancer: advisory report 31-03-2025. The Health Council of the Netherlands https:\/\/www.healthcouncil.nl\/documents\/2025\/03\/31\/screening-for-lung-cancer (2025)."},{"key":"1131_CR27","unstructured":"4-IN-THE-LUNG-RUN: population-based lung cancer screening trial. 4inthelungrun https:\/\/4inthelungrun.com\/en-gb (2026)."},{"key":"1131_CR28","unstructured":"Revel, M.-P. et al. US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05195385 (2022)."},{"key":"1131_CR29","unstructured":"Vogel-Claussen, J. US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04913155 (2021)."},{"key":"1131_CR30","unstructured":"Trujillo-Reyes, J. C. & Seijo, L. US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06157957 (2023)."},{"key":"1131_CR31","unstructured":"Strengthening the screening of lung cancer in Europe. European Lung Foundation www.europeanlung.org\/solace (2025)."},{"key":"1131_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(25)00082-8","volume":"26","author":"A Bhamani","year":"2025","unstructured":"Bhamani, A. et al. Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study. Lancet Oncol. 26, 609\u2013619\u00a0(2025).","journal-title":"Lancet Oncol."},{"key":"1131_CR33","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein, E. A. et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 32, 1167\u20131177 (2021).","journal-title":"Ann. Oncol."},{"key":"1131_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJMoa1211776","volume":"368","author":"MC Tammem\u00e4gi","year":"2013","unstructured":"Tammem\u00e4gi, M. C. et al. Selection criteria for lung-cancer screening. N. Engl. J. Med. 368, 728\u2013736 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1470-2045(21)00590-8","volume":"23","author":"MC Tammem\u00e4gi","year":"2022","unstructured":"Tammem\u00e4gi, M. C. et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 23, 138\u2013148 (2022).","journal-title":"Lancet Oncol."},{"key":"1131_CR36","unstructured":"Target screening for lung cancer in individuals at increased risk. UK National Screening Committee https:\/\/view-health-screening-recommendations.service.gov.uk\/lung-cancer\/ (2022)."},{"key":"1131_CR37","unstructured":"Lung cancer screening. Cancer Research UK https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-screening\/lung-cancer-screening (2024)."},{"key":"1131_CR38","unstructured":"State of lung cancer. American Lung Association http:\/\/www.lung.org\/research\/state-of-lung-cancer (2024)."},{"key":"1131_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.chest.2023.02.003","volume":"164","author":"GA Silvestri","year":"2023","unstructured":"Silvestri, G. A. et al. Outcomes from more than 1 million people screened for lung cancer with low-dose CT imaging. Chest 164, 241\u2013251 (2023).","journal-title":"Chest"},{"key":"1131_CR40","unstructured":"Albus, K. Lung cancer screening center designation. American College of Radiology https:\/\/accreditationsupport.acr.org\/support\/solutions\/articles\/11000061040-lung-cancer-screening-center-designation-revised-7-22-2024 (2024)."},{"key":"1131_CR41","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.21037\/tlcr-20-985","volume":"10","author":"CM van der Aalst","year":"2021","unstructured":"van der Aalst, C. M., Ten Haaf, K. & de Koning, H. J. Implementation of lung cancer screening: what are the main issues? Transl. Lung Cancer Res. 10, 1050\u20131063 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"1131_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jtho.2020.10.127","volume":"16","author":"J Sands","year":"2021","unstructured":"Sands, J. et al. Lung screening benefits and challenges: a review of the data and outline for implementation. J. Thorac. Oncol. 16, 37\u201353 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.pmedr.2018.05.013","volume":"11","author":"JM Eberth","year":"2018","unstructured":"Eberth, J. M. et al. A national survey of primary care physicians: perceptions and practices of low-dose CT lung cancer screening. Prev. Med. Rep. 11, 93\u201399 (2018).","journal-title":"Prev. Med. Rep."},{"key":"1131_CR44","unstructured":"NCQA Communications. NCQA\u2019s lung cancer screening measure: updates and next steps. National Committee for Quality Assurance https:\/\/www.ncqa.org\/blog\/ncqas-lung-cancer-screening-measure-updates-and-next-steps\/ (2025)."},{"key":"1131_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks, L. E. L. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Primers 10, 71 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1131_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2025.11.008","volume":"37","author":"Y Wang","year":"2026","unstructured":"Wang, Y. et al. Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma. Ann. Oncol. 37, 289\u2013313 (2026).","journal-title":"Ann. Oncol."},{"key":"1131_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473778","volume":"45","author":"CM Czerlanis","year":"2025","unstructured":"Czerlanis, C. M. et al. Broadening the net: overcoming challenges and embracing novel technologies in lung cancer screening. Am. Soc. Clin. Oncol. Educ. Book 45, e473778 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1131_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/1740774510396742","volume":"8","author":"C Duda","year":"2011","unstructured":"Duda, C. et al. Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial. Clin. Trials 8, 214\u2013223 (2011).","journal-title":"Clin. Trials"},{"key":"1131_CR49","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamaoncol.2019.1402","volume":"5","author":"MC Aldrich","year":"2019","unstructured":"Aldrich, M. C. et al. Evaluation of USPSTF lung cancer screening guidelines among African American adult smokers. JAMA Oncol. 5, 1318\u20131324 (2019).","journal-title":"JAMA Oncol."},{"key":"1131_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacr.2018.12.028","volume":"16","author":"AK Borondy Kitts","year":"2019","unstructured":"Borondy Kitts, A. K. The patient perspective on lung cancer screening and health disparities. J. Am. Coll. Radiol. 16, 601\u2013606 (2019).","journal-title":"J. Am. Coll. Radiol."},{"key":"1131_CR51","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1200\/JCO.23.01780","volume":"42","author":"AL Potter","year":"2024","unstructured":"Potter, A. L. et al. Pack-year smoking history: an inadequate and biased measure to determine lung cancer screening eligibility. J. Clin. Oncol. 42, 2026\u20132037 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR52","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening. Version 1.2026 (National Comprehensive Cancer Network, 2025)."},{"key":"1131_CR53","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.chest.2023.10.028","volume":"165","author":"J Christensen","year":"2024","unstructured":"Christensen, J. et al. ACR Lung-RADS v2022: assessment categories and management recommendations. Chest 165, 738\u2013753 (2024).","journal-title":"Chest"},{"key":"1131_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.7326\/M14-2086","volume":"162","author":"PF Pinsky","year":"2015","unstructured":"Pinsky, P. F. et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann. Intern. Med. 162, 485\u2013491 (2015).","journal-title":"Ann. Intern. Med."},{"key":"1131_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","volume":"616","author":"W Hill","year":"2023","unstructured":"Hill, W. et al. Lung adenocarcinoma promotion by air pollutants. Nature 616, 159\u2013167 (2023).","journal-title":"Nature"},{"key":"1131_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38196-z","volume":"14","author":"J Shi","year":"2023","unstructured":"Shi, J. et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat. Commun. 14, 3043 (2023).","journal-title":"Nat. Commun."},{"key":"1131_CR57","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/JTO.0000000000000130","volume":"9","author":"A Gazdar","year":"2014","unstructured":"Gazdar, A. et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J. Thorac. Oncol. 9, 456\u2013463 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR58","doi-asserted-by":"publisher","first-page":"djt338","DOI":"10.1093\/jnci\/djt338","volume":"106","author":"H Yamamoto","year":"2014","unstructured":"Yamamoto, H. et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J. Natl Cancer Inst. 106, djt338 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR59","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1200\/JCO.23.01372","volume":"41","author":"GR Oxnard","year":"2023","unstructured":"Oxnard, G. R. et al. Germline EGFR mutations and familial lung cancer. J. Clin. Oncol. 41, 5274\u20135284 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR60","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.jtho.2023.06.018","volume":"18","author":"CL Wang","year":"2023","unstructured":"Wang, C. L. et al. Low-dose computed tomography screening in relatives with a family history of lung cancer. J. Thorac. Oncol. 18, 1492\u20131503 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR61","doi-asserted-by":"publisher","first-page":"2301736","DOI":"10.1183\/13993003.01736-2023","volume":"63","author":"J Cai","year":"2024","unstructured":"Cai, J. et al. Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach. Eur. Respir. J. 63, 2301736 (2024).","journal-title":"Eur. Respir. J."},{"key":"1131_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2213-2600(23)00338-7","volume":"12","author":"GC Chang","year":"2024","unstructured":"Chang, G. C. et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir. Med. 12, 141\u2013152 (2024).","journal-title":"Lancet Respir. Med."},{"key":"1131_CR63","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1056\/NEJMoa1209120","volume":"368","author":"TR Church","year":"2013","unstructured":"Church, T. R. et al. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368, 1980\u20131991 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR64","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1102\/1470-7330.2011.9020","volume":"11","author":"Y Ru Zhao","year":"2011","unstructured":"Ru Zhao, Y. et al. NELSON lung cancer screening study. Cancer Imaging 11, S79\u2013S84 (2011).","journal-title":"Cancer Imaging"},{"key":"1131_CR65","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2024.42.16_suppl.8009","volume":"42","author":"P-C Yang","year":"2024","unstructured":"Yang, P.-C., Chen, T. H.-H., Huang, K.-P., Lin, L.-J. & Wu, C.-C. Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer. J. Clin. Oncol. 42, 8009 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR66","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/JCO.2023.41.16_suppl.8510","volume":"41","author":"E Shum","year":"2023","unstructured":"Shum, E. et al. Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS). J. Clin. Oncol. 41, 8510\u20138510 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR67","doi-asserted-by":"crossref","unstructured":"Shum, E. et al. Female Asian Nonsmoker Screening Study (FANSS): A U.S. Based Lung Cancer Screening Program in a Non-Smoking Population. In 2025 World Conference on Lung Cancer (2025).","DOI":"10.1016\/j.jtho.2025.09.084"},{"key":"1131_CR68","unstructured":"Lai, G. G. Y. et al. Preliminary Results of the Singapore Lung Cancer Screening Through Integrating CT With Other Biomarkers (SOLSTICE) Study. In 2025 World Conference on Lung Cancer (2025)."},{"key":"1131_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2013.10.008","volume":"83","author":"JR Jett","year":"2014","unstructured":"Jett, J. R. et al. Audit of the autoantibody test, EarlyCDT-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer 83, 51\u201355 (2014).","journal-title":"Lung Cancer"},{"key":"1131_CR70","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245\u2013251 (2020).","journal-title":"Nature"},{"key":"1131_CR71","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1940-6207.CAPR-21-0075","volume":"14","author":"AM Fendrick","year":"2021","unstructured":"Fendrick, A. M. et al. Impact of patient adherence to stool-based colorectal cancer screening and colonoscopy following a positive test on clinical outcomes. Cancer Prev. Res. 14, 845\u2013850 (2021).","journal-title":"Cancer Prev. Res."},{"key":"1131_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08678-8","volume":"21","author":"S Ioannou","year":"2021","unstructured":"Ioannou, S., Sutherland, K., Sussman, D. A. & Deshpande, A. R. Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing. BMC Cancer 21, 966 (2021).","journal-title":"BMC Cancer"},{"key":"1131_CR73","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1001\/jama.2021.4417","volume":"325","author":"JS Lin","year":"2021","unstructured":"Lin, J. S., Perdue, L. A., Henrikson, N. B., Bean, S. I. & Blasi, P. R. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 325, 1978\u20131998 (2021).","journal-title":"JAMA"},{"key":"1131_CR74","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","volume":"14","author":"PJ Mazzone","year":"2024","unstructured":"Mazzone, P. J. et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 14, 2224\u20132242 (2024).","journal-title":"Cancer Discov."},{"key":"1131_CR75","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.athoracsur.2025.01.003","volume":"119","author":"AL Potter","year":"2025","unstructured":"Potter, A. L. et al. Assessing lung cancer screening eligibility of patients with lung cancer in the Boston Lung Cancer Study: an analysis of 7186 lung cancer cases. Ann. Thorac. Surg. 119, 768\u2013776 (2025).","journal-title":"Ann. Thorac. Surg."},{"key":"1131_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","volume":"18","author":"M Oudkerk","year":"2021","unstructured":"Oudkerk, M., Liu, S., Heuvelmans, M. A., Walter, J. E. & Field, J. K. Lung cancer LDCT screening and mortality reduction \u2014 evidence, pitfalls and future perspectives. Nat. Rev. Clin. Oncol. 18, 135\u2013151 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR77","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1164\/rccm.201505-0990OC","volume":"192","author":"MK Gould","year":"2015","unstructured":"Gould, M. K. et al. Recent trends in the identification of incidental pulmonary nodules. Am. J. Respir. Crit. Care Med. 192, 1208\u20131214 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1131_CR78","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1183\/09031936.00222914","volume":"45","author":"M Infante","year":"2015","unstructured":"Infante, M. A conservative approach for subsolid lung nodules: is it safe enough? Eur. Respir. J. 45, 592\u2013595 (2015).","journal-title":"Eur. Respir. J."},{"key":"1131_CR79","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.21037\/jtd.2017.08.89","volume":"9","author":"JG Cohen","year":"2017","unstructured":"Cohen, J. G. & Ferretti, G. R. Pure ground-glass nodules: are they really indolent? J. Thorac. Dis. 9, 2839\u20132842 (2017).","journal-title":"J. Thorac. Dis."},{"key":"1131_CR80","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.21037\/tlcr.2019.10.16","volume":"8","author":"Y Kobayashi","year":"2019","unstructured":"Kobayashi, Y. & Mitsudomi, T. Ground glass nodules with 5 years\u2019 stability can grow after 10-year follow-up: do genetic features determine the fate? Transl. Lung Cancer Res. 8, S425\u2013s427 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"1131_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0232-6","volume":"19","author":"H Lu","year":"2019","unstructured":"Lu, H. et al. Multi-window CT based radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial: a retrospective study. Cancer Imaging 19, 45 (2019).","journal-title":"Cancer Imaging"},{"key":"1131_CR82","doi-asserted-by":"publisher","first-page":"e93S","DOI":"10.1378\/chest.12-2351","volume":"143","author":"MK Gould","year":"2013","unstructured":"Gould, M. K. et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e93S\u2013e120S (2013).","journal-title":"Chest"},{"key":"1131_CR83","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacr.2023.09.009","volume":"21","author":"J Christensen","year":"2024","unstructured":"Christensen, J. et al. ACR Lung-RADS v2022: assessment categories and management recommendations. J. Am. Coll. Radiol. 21, 473\u2013488 (2024).","journal-title":"J. Am. Coll. Radiol."},{"key":"1131_CR84","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2015-207168","volume":"70","author":"ME Callister","year":"2015","unstructured":"Callister, M. E. et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70, ii1\u2013ii54 (2015).","journal-title":"Thorax"},{"key":"1131_CR85","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2017161659","volume":"284","author":"H MacMahon","year":"2017","unstructured":"MacMahon, H. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 284, 228\u2013243 (2017).","journal-title":"Radiology"},{"key":"1131_CR86","doi-asserted-by":"publisher","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely, G. J. et al. NCCN Guidelines insights: non-small cell lung cancer, version 7.2025. J. Natl Compr. Canc Netw. 23, 354\u2013362 (2025).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1131_CR87","doi-asserted-by":"publisher","first-page":"200013","DOI":"10.1183\/20734735.0013-2020","volume":"16","author":"J Brodersen","year":"2020","unstructured":"Brodersen, J. et al. Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials. Breathe 16, 200013 (2020).","journal-title":"Breathe"},{"key":"1131_CR88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S2213-2600(20)30553-1","volume":"9","author":"MEJ Callister","year":"2021","unstructured":"Callister, M. E. J., Sasieni, P. & Robbins, H. A. Overdiagnosis in lung cancer screening. Lancet Respir. Med. 9, 7\u20139 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1131_CR89","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2020.12.031","volume":"153","author":"DD Durham","year":"2021","unstructured":"Durham, D. D., Croswell, J. M. & Marcus, P. M. Do competing causes of mortality contribute to overdiagnosis in lung cancer screening? Lung Cancer 153, 21\u201324 (2021).","journal-title":"Lung Cancer"},{"key":"1131_CR90","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.jtcvs.2019.09.030","volume":"159","author":"ML Madariaga","year":"2020","unstructured":"Madariaga, M. L. et al. Multidisciplinary selection of pulmonary nodules for surgical resection: diagnostic results and long-term outcomes. J. Thorac. Cardiovasc. Surg. 159, 1558\u20131566.e1553 (2020).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"1131_CR91","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: images are more than pictures, they are data. Radiology 278, 563\u2013577 (2016).","journal-title":"Radiology"},{"key":"1131_CR92","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1055-9965.EPI-20-0075","volume":"29","author":"RJ Gillies","year":"2020","unstructured":"Gillies, R. J. & Schabath, M. B. Radiomics improves cancer screening and early detection. Cancer Epidemiol. Biomarkers Prev. 29, 2556\u20132567 (2020).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1131_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJ Aerts","year":"2014","unstructured":"Aerts, H. J. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun. 5, 4006 (2014).","journal-title":"Nat. Commun."},{"key":"1131_CR94","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.21037\/tlcr-20-708","volume":"10","author":"F Binczyk","year":"2021","unstructured":"Binczyk, F., Prazuch, W., Bozek, P. & Polanska, J. Radiomics and artificial intelligence in lung cancer screening. Transl. Lung Cancer Res. 10, 1186\u20131199 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"1131_CR95","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1148\/radiol.2017161458","volume":"286","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Radiologic features of small pulmonary nodules and lung cancer risk in the National Lung Screening Trial: a nested case\u2013control study. Radiology 286, 298\u2013306 (2018).","journal-title":"Radiology"},{"key":"1131_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1148\/radiol.2017162725","volume":"286","author":"P Huang","year":"2018","unstructured":"Huang, P. et al. Added value of computer-aided CT image features for early lung cancer diagnosis with small pulmonary nodules: a matched case\u2013control study. Radiology 286, 286\u2013295 (2018).","journal-title":"Radiology"},{"key":"1131_CR97","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-019-0447-x","volume":"25","author":"D Ardila","year":"2019","unstructured":"Ardila, D. et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat. Med. 25, 954\u2013961 (2019).","journal-title":"Nat. Med."},{"key":"1131_CR98","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1200\/JCO.22.01345","volume":"41","author":"M PG","year":"2023","unstructured":"PG, M. et al. Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography. J. Clin. Oncol. 41, 2191\u20132200 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR99","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2967\/jnumed.116.177592","volume":"58","author":"JD Schaefferkoetter","year":"2017","unstructured":"Schaefferkoetter, J. D. et al. Quantitative accuracy and lesion detectability of low-dose 18F-FDG PET for lung cancer screening. J. Nucl. Med. 58, 399\u2013405 (2017).","journal-title":"J. Nucl. Med."},{"key":"1131_CR100","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.xcrm.2024.101463","volume":"5","author":"M Salehjahromi","year":"2024","unstructured":"Salehjahromi, M. et al. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: proof of concept. Cell Rep. Med. 5, 101463 (2024).","journal-title":"Cell Rep. Med."},{"key":"1131_CR101","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1001\/jama.2011.1591","volume":"306","author":"MM Oken","year":"2011","unstructured":"Oken, M. M. et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306, 1865\u20131873 (2011).","journal-title":"JAMA"},{"key":"1131_CR102","doi-asserted-by":"publisher","first-page":"101744","DOI":"10.1016\/j.artmed.2019.101744","volume":"103","author":"X Li","year":"2020","unstructured":"Li, X. et al. Multi-resolution convolutional networks for chest X-ray radiograph based lung nodule detection. Artif. Intell. Med. 103, 101744 (2020).","journal-title":"Artif. Intell. Med."},{"key":"1131_CR103","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2589-7500(22)00063-2","volume":"4","author":"JW Gichoya","year":"2022","unstructured":"Gichoya, J. W. et al. AI recognition of patient race in medical imaging: a modelling study. Lancet Digit. Health 4, e406\u2013e414 (2022).","journal-title":"Lancet Digit. Health"},{"key":"1131_CR104","first-page":"375","volume":"117","author":"S Dubin","year":"2020","unstructured":"Dubin, S. & Griffin, D. Lung cancer in non-smokers. Mo. Med. 117, 375\u2013379 (2020).","journal-title":"Mo. Med."},{"key":"1131_CR105","doi-asserted-by":"publisher","first-page":"20211368","DOI":"10.1259\/bjr.20211368","volume":"96","author":"R Munden","year":"2023","unstructured":"Munden, R. Incidentalomas in chest CT. Br. J. Radiol. 96, 20211368 (2023).","journal-title":"Br. J. Radiol."},{"key":"1131_CR106","doi-asserted-by":"publisher","first-page":"100441","DOI":"10.1016\/j.ejro.2022.100441","volume":"9","author":"MM Chen","year":"2022","unstructured":"Chen, M. M. et al. Artificial intelligence in oncologic imaging. Eur. J. Radiol. Open 9, 100441 (2022).","journal-title":"Eur. J. Radiol. Open"},{"key":"1131_CR107","doi-asserted-by":"publisher","unstructured":"Raza, S. et al. Who is responsible? The data, models, users or regulations? Responsible generative AI for a sustainable future. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2502.08650 (2025).","DOI":"10.48550\/arXiv.2502.08650"},{"key":"1131_CR108","doi-asserted-by":"publisher","first-page":"AIoa2300030","DOI":"10.1056\/AIoa2300030","volume":"1","author":"K Wu","year":"2024","unstructured":"Wu, K. et al. Characterizing the clinical adoption of medical AI devices through US insurance claims. NEJM AI 1, AIoa2300030 (2024).","journal-title":"NEJM AI"},{"key":"1131_CR109","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.2013.50.4357","volume":"32","author":"G Sozzi","year":"2014","unstructured":"Sozzi, G. et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32, 768\u2013773 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR110","doi-asserted-by":"publisher","first-page":"djv063","DOI":"10.1093\/jnci\/djv063","volume":"107","author":"F Montani","year":"2015","unstructured":"Montani, F. et al. miR-Test: a blood test for lung cancer early detection. J. Natl Cancer Inst. 107, djv063 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR111","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-2600(20)30081-3","volume":"8","author":"CH Marquette","year":"2020","unstructured":"Marquette, C. H. et al. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respir. Med. 8, 709\u2013716 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1131_CR112","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/cncy.22278","volume":"128","author":"RL Katz","year":"2020","unstructured":"Katz, R. L. et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules. Cancer Cytopathol. 128, 553\u2013562 (2020).","journal-title":"Cancer Cytopathol."},{"key":"1131_CR113","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926\u2013930 (2018).","journal-title":"Science"},{"key":"1131_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37979-8","volume":"14","author":"D Albanes","year":"2023","unstructured":"Albanes, D. et al. The blood proteome of imminent lung cancer diagnosis. Nat. Commun. 14, 3042 (2023).","journal-title":"Nat. Commun."},{"key":"1131_CR115","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745\u2013759 (2020).","journal-title":"Ann. Oncol."},{"key":"1131_CR116","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmoldx.2024.06.007","volume":"26","author":"S Chowdhury","year":"2024","unstructured":"Chowdhury, S. et al. Analytical validation of an early detection pancreatic cancer test using 5-hydroxymethylation signatures. J. Mol. Diagn. 26, 888\u2013896 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1131_CR117","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"1131_CR118","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.jlb.2023.100001","volume":"1","author":"R Rosell","year":"2023","unstructured":"Rosell, R. et al. Liquid biopsy in detecting early non-small cell lung cancer. J. Liq. Biopsy 1, 100001 (2023).","journal-title":"J. Liq. Biopsy"},{"key":"1131_CR119","doi-asserted-by":"publisher","first-page":"S1605","DOI":"10.1016\/j.annonc.2025.09.076","volume":"36","author":"N Nabavizadeh","year":"2025","unstructured":"Nabavizadeh, N. et al. LBA64 Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER II study. Ann. Oncol. 36, S1605 (2025).","journal-title":"Ann. Oncol."},{"key":"1131_CR120","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/ijms24032505","volume":"24","author":"GMS Casagrande","year":"2023","unstructured":"Casagrande, G. M. S., Silva, M. O., Reis, R. M. & Leal, L. F. Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int. J. Mol. Sci. 24, 2505 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1131_CR121","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung, D. C. et al. A cell-free DNA blood-based test for colorectal cancer screening. N. Engl. J. Med. 390, 973\u2013983 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR122","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1158\/1055-9965.EPI-25-0903","volume":"34","author":"E LeeVan","year":"2025","unstructured":"LeeVan, E. et al. Framework to select multi-cancer detection assays in the National Cancer Institute\u2019s Vanguard Study. Cancer Epidemiol. Biomarkers Prev. 34, 1787\u20131793 (2025).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1131_CR123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/ANNALS-25-01877","volume":"178","author":"LC Kahwati","year":"2025","unstructured":"Kahwati, L. C. et al. Multicancer detection tests for screening: a systematic review. Ann. Intern. Med. 178, 11 (2025).","journal-title":"Ann. Intern. Med."},{"key":"1131_CR124","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1073\/pnas.1100048108","volume":"108","author":"M Boeri","year":"2011","unstructured":"Boeri, M. et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl Acad. Sci. USA 108, 3713\u20133718 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1131_CR125","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","volume":"33","author":"U Pastorino","year":"2022","unstructured":"Pastorino, U. et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann. Oncol. 33, 395\u2013405 (2022).","journal-title":"Ann. Oncol."},{"key":"1131_CR126","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamaoncol.2020.0001","volume":"6","author":"T Fehlmann","year":"2020","unstructured":"Fehlmann, T. et al. Evaluating the use of circulating microrna profiles for lung cancer detection in symptomatic patients. JAMA Oncol. 6, 714\u2013723 (2020).","journal-title":"JAMA Oncol."},{"key":"1131_CR127","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi, A. et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40, 1537\u20131549 e1512 (2022).","journal-title":"Cancer Cell"},{"key":"1131_CR128","unstructured":"Division of Cancer Prevention. Vanguard study. National Cancer Institute https:\/\/prevention.cancer.gov\/research-areas\/networks-consortia-programs\/csrn\/vanguard-study (2026)."},{"key":"1131_CR129","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/clinchem\/hvaa258","volume":"66","author":"RWK Chiu","year":"2020","unstructured":"Chiu, R. W. K., Heitzer, E., Lo, Y. M. D., Mouliere, F. & Tsui, D. W. Y. Cell-free DNA fragmentomics: the new \u201comics\u201d on the block. Clin. Chem. 66, 1480\u20131484 (2020).","journal-title":"Clin. Chem."},{"key":"1131_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111597","volume":"9","author":"M Ilie","year":"2014","unstructured":"Ilie, M. et al. \u201cSentinel\u201d circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS ONE 9, e111597 (2014).","journal-title":"PLoS ONE"},{"key":"1131_CR131","doi-asserted-by":"publisher","first-page":"eabb9601","DOI":"10.1126\/science.abb9601","volume":"369","author":"AM Lennon","year":"2020","unstructured":"Lennon, A. M. et al. Feasibility of blood testing combined with PET\u2013CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020).","journal-title":"Science"},{"key":"1131_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102769","volume":"75","author":"Y Jin","year":"2024","unstructured":"Jin, Y. et al. Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG). EClinicalMedicine 75, 102769 (2024).","journal-title":"EClinicalMedicine"},{"key":"1131_CR133","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.annonc.2020.05.028","volume":"31","author":"C Fiala","year":"2020","unstructured":"Fiala, C. & Diamandis, E. P. A multi-cancer detection test: focus on the positive predictive value. Ann. Oncol. 31, 1267\u20131268 (2020).","journal-title":"Ann. Oncol."},{"key":"1131_CR134","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402, 1251\u20131260 (2023).","journal-title":"Lancet"},{"key":"1131_CR135","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1940-6207.CAPR-23-0451","volume":"17","author":"AM Lennon","year":"2024","unstructured":"Lennon, A. M. et al. Outcomes following a false positive multi-cancer early detection (MCED) test: results from DETECT-A, the first large, prospective, interventional MCED study. Cancer Prev. Res. 17, 355\u2013359 (2024).","journal-title":"Cancer Prev. Res."},{"key":"1131_CR136","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-24-0797","volume":"30","author":"RT Sundby","year":"2024","unstructured":"Sundby, R. T. et al. Early detection of malignant and premalignant peripheral nerve tumors using cell-free DNA fragmentomics. Clin. Cancer Res. 30, 4363\u20134376 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120552","volume":"578","author":"R Baskar","year":"2026","unstructured":"Baskar, R. et al. Non-invasive biomarkers in lung cancer. Clin. Chim. Acta 578, 120552 (2026).","journal-title":"Clin. Chim. Acta"},{"key":"1131_CR138","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2815","volume":"5","author":"GB Hanna","year":"2019","unstructured":"Hanna, G. B., Boshier, P. R., Markar, S. R. & Romano, A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: a systematic review and meta-analysis. JAMA Oncol. 5, e182815 (2019).","journal-title":"JAMA Oncol."},{"key":"1131_CR139","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-021-00389-3","volume":"21","author":"GA Kwong","year":"2021","unstructured":"Kwong, G. A. et al. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat. Rev. Cancer 21, 655\u2013668 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR140","doi-asserted-by":"publisher","first-page":"027106","DOI":"10.1088\/1752-7155\/6\/2\/027106","volume":"6","author":"PJ Mazzone","year":"2012","unstructured":"Mazzone, P. J. Exhaled breath volatile organic compound biomarkers in lung cancer. J. Breath Res. 6, 027106 (2012).","journal-title":"J. Breath Res."},{"key":"1131_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2024.135856","volume":"480","author":"M Yan","year":"2024","unstructured":"Yan, M. et al. Volatile organic compound exposure in relation to lung cancer: insights into mechanisms of action through metabolomics. J. Hazard. Mater. 480, 135856 (2024).","journal-title":"J. Hazard. Mater."},{"key":"1131_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12537-7","volume":"24","author":"X Fan","year":"2024","unstructured":"Fan, X. et al. Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis. BMC Cancer 24, 775 (2024).","journal-title":"BMC Cancer"},{"key":"1131_CR143","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/metabo9030052","volume":"9","author":"Z Jia","year":"2019","unstructured":"Jia, Z., Patra, A., Kutty, V. K. & Venkatesan, T. Critical review of volatile organic compound analysis in breath and in vitro cell culture for detection of lung cancer. Metabolites 9, 52 (2019).","journal-title":"Metabolites"},{"key":"1131_CR144","unstructured":"Lung cancer prevention (PDQ) \u2014 health professional version. National Cancer Institute https:\/\/www.cancer.gov\/types\/lung\/hp\/lung-prevention-pdq (2025)."},{"key":"1131_CR145","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.seminoncol.2022.02.001","volume":"49","author":"RL Keith","year":"2022","unstructured":"Keith, R. L. et al. Lung cancer: premalignant biology and medical prevention. Semin. Oncol. 49, 254\u2013260 (2022).","journal-title":"Semin. Oncol."},{"key":"1131_CR146","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41568-025-00791-1","volume":"25","author":"SA Mazzilli","year":"2025","unstructured":"Mazzilli, S. A. et al. Translating premalignant biology to accelerate non-small-cell lung cancer interception. Nat. Rev. Cancer 25, 379\u2013392 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR147","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1940-6207.CAPR-11-0195","volume":"4","author":"EH Blackburn","year":"2011","unstructured":"Blackburn, E. H. Cancer interception. Cancer Prev. Res. 4, 787\u2013792 (2011).","journal-title":"Cancer Prev. Res."},{"key":"1131_CR148","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa1100370","volume":"366","author":"AG Zauber","year":"2012","unstructured":"Zauber, A. G. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366, 687\u2013696 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR149","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"C Correa","year":"2010","unstructured":"Correa, C. et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl Cancer Inst. Monogr. 2010, 162\u2013177 (2010).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"1131_CR150","unstructured":"Wild, C. P., Stewart, B. W. & Wild, C. World Cancer Report 2014 (World Health Organization, 2014)."},{"key":"1131_CR151","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ccm.2011.08.002","volume":"32","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck, F. C. & Homer, R. J. Approach to the ground-glass nodule. Clin. Chest Med. 32, 799\u2013810 (2011).","journal-title":"Clin. Chest Med."},{"key":"1131_CR152","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.ejcts.2008.07.044","volume":"34","author":"K Kodama","year":"2008","unstructured":"Kodama, K. et al. Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study. Eur. J. Cardiothorac. Surg. 34, 1068\u20131074 (2008).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1131_CR153","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jtcvs.2007.06.010","volume":"134","author":"M Mun","year":"2007","unstructured":"Mun, M. & Kohno, T. Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter. J. Thorac. Cardiovasc. Surg. 134, 877\u2013882 (2007).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"1131_CR154","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejcts.2006.03.058","volume":"30","author":"T Ohtsuka","year":"2006","unstructured":"Ohtsuka, T., Watanabe, K., Kaji, M., Naruke, T. & Suemasu, K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur. J. Cardiothorac. Surg. 30, 160\u2013163 (2006).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1131_CR155","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1158\/1078-0432.CCR-16-0695","volume":"22","author":"A Albini","year":"2016","unstructured":"Albini, A., DeCensi, A., Cavalli, F. & Costa, A. Cancer prevention and interception: a new era for chemopreventive approaches. Clin. Cancer Res. 22, 4322\u20134327 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR156","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1164\/rccm.202406-1168ST","volume":"210","author":"SJ Moghaddam","year":"2024","unstructured":"Moghaddam, S. J. et al. Premalignant progression in the lung: knowledge gaps and novel opportunities for interception of non-small cell lung cancer. an official American Thoracic Society research statement. Am. J. Respir. Crit. Care Med. 210, 548\u2013571 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1131_CR157","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa1312547","volume":"371","author":"WC Black","year":"2014","unstructured":"Black, W. C. et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N. Engl. J. Med. 371, 1793\u20131802 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR158","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10555-010-9214-7","volume":"29","author":"T Ishizumi","year":"2010","unstructured":"Ishizumi, T., McWilliams, A., MacAulay, C., Gazdar, A. & Lam, S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 29, 5\u201314 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"1131_CR159","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group.","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group. Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N. Engl. J. Med. 321, 129\u2013135 (1989).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR160","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jnci\/92.12.977","volume":"92","author":"N van Zandwijk","year":"2000","unstructured":"van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N. & van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl Cancer Inst. 92, 977\u2013986 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR161","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto, R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. 296, 313\u2013316 (1988).","journal-title":"Br. Med. J."},{"key":"1131_CR162","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.200709-1398OC","volume":"177","author":"CG Slatore","year":"2008","unstructured":"Slatore, C. G., Littman, A. J., Au, D. H., Satia, J. A. & White, E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am. J. Respir. Crit. Care Med. 177, 524\u2013530 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1131_CR163","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1753-4887.1994.tb01430.x","volume":"52","author":"J Blumberg","year":"1994","unstructured":"Blumberg, J. & Block, G. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. Nutr. Rev. 52, 242\u2013245 (1994).","journal-title":"Nutr. Rev."},{"key":"1131_CR164","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial. JAMA 294, 47\u201355 (2005).","journal-title":"JAMA"},{"key":"1131_CR165","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/jnci\/88.21.1550","volume":"88","author":"GS Omenn","year":"1996","unstructured":"Omenn, G. S. et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl Cancer Inst. 88, 1550\u20131559 (1996).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR166","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2013.49.2173","volume":"31","author":"DD Karp","year":"2013","unstructured":"Karp, D. D. et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J. Clin. Oncol. 31, 4179\u20134187 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR167","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/93.8.605","volume":"93","author":"SM Lippman","year":"2001","unstructured":"Lippman, S. M. et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl Cancer Inst. 93, 605\u2013618 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"1131_CR168","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2020.03.053","volume":"181","author":"O Rozenblatt-Rosen","year":"2020","unstructured":"Rozenblatt-Rosen, O. et al. The Human Tumor Atlas Network: charting tumor transitions across space and time at single-cell resolution. Cell 181, 236\u2013249 (2020).","journal-title":"Cell"},{"key":"1131_CR169","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1158\/1940-6207.CAPR-22-0435","volume":"16","author":"S Srivastava","year":"2023","unstructured":"Srivastava, S., Wagner, P. D., Hughes, S. K. & Ghosh, S. PreCancer Atlas: present and future. Cancer Prev. Res. 16, 379\u2013384 (2023).","journal-title":"Cancer Prev. Res."},{"key":"1131_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10877-8","volume":"10","author":"X Hu","year":"2019","unstructured":"Hu, X. et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat. Commun. 10, 2978 (2019).","journal-title":"Nat. Commun."},{"key":"1131_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20907-z","volume":"12","author":"X Hu","year":"2021","unstructured":"Hu, X. et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat. Commun. 12, 687 (2021).","journal-title":"Nat. Commun."},{"key":"1131_CR172","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J. Thorac. Oncol. 14, 1912\u20131923 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR173","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.202101-0119OC","volume":"204","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. Multiomics analysis reveals distinct immunogenomic features of lung cancer with ground-glass opacity. Am. J. Respir. Crit. Care Med. 204, 1180\u20131192 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1131_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22890-x","volume":"12","author":"H Dejima","year":"2021","unstructured":"Dejima, H. et al. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat. Commun. 12, 2722 (2021).","journal-title":"Nat. Commun."},{"key":"1131_CR175","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1940-6207.CAPR-13-0372","volume":"7","author":"AT Ooi","year":"2014","unstructured":"Ooi, A. T. et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev. Res. 7, 487\u2013495 (2014).","journal-title":"Cancer Prev. Res."},{"key":"1131_CR176","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1158\/1078-0432.CCR-16-2540","volume":"23","author":"J Beane","year":"2017","unstructured":"Beane, J. et al. Detecting the presence and progression of premalignant lung lesions via airway gene expression. Clin. Cancer Res. 23, 5091\u20135100 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09834-2","volume":"10","author":"JE Beane","year":"2019","unstructured":"Beane, J. E. et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat. Commun. 10, 1856 (2019).","journal-title":"Nat. Commun."},{"key":"1131_CR178","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41591-018-0323-0","volume":"25","author":"VH Teixeira","year":"2019","unstructured":"Teixeira, V. H. et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat. Med. 25, 517\u2013525 (2019).","journal-title":"Nat. Med."},{"key":"1131_CR179","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","volume":"571","author":"C Mascaux","year":"2019","unstructured":"Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570\u2013575 (2019).","journal-title":"Nature"},{"key":"1131_CR180","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.coph.2004.03.010","volume":"4","author":"CA Dinarello","year":"2004","unstructured":"Dinarello, C. A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 4, 378\u2013385 (2004).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1131_CR181","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.4049\/jimmunol.151.7.3500","volume":"151","author":"DJ McKean","year":"1993","unstructured":"McKean, D. J. et al. Murine T helper cell-2 lymphocytes express type I and type II IL-1 receptors, but only the type I receptor mediates costimulatory activity. J. Immunol. 151, 3500\u20133510 (1993).","journal-title":"J. Immunol."},{"key":"1131_CR182","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cyto.2008.07.014","volume":"43","author":"G Germano","year":"2008","unstructured":"Germano, G., Allavena, P. & Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374\u2013379 (2008).","journal-title":"Cytokine"},{"key":"1131_CR183","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF03256210","volume":"10","author":"J Copier","year":"2006","unstructured":"Copier, J., Whelan, M. & Dalgleish, A. Biomarkers for the development of cancer vaccines: current status. Mol. Diagn. Ther. 10, 337\u2013343 (2006).","journal-title":"Mol. Diagn. Ther."},{"key":"1131_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57285-y","volume":"10","author":"R Li","year":"2020","unstructured":"Li, R. et al. Chronic IL-1\u03b2-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Sci. Rep. 10, 377 (2020).","journal-title":"Sci. Rep."},{"key":"1131_CR185","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157788","volume":"7","author":"B Yuan","year":"2022","unstructured":"Yuan, B. et al. Targeting IL-1\u03b2 as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer. JCI Insight 7, e157788 (2022).","journal-title":"JCI Insight"},{"key":"1131_CR186","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.celrep.2016.05.085","volume":"16","author":"AG McLoed","year":"2016","unstructured":"McLoed, A. G. et al. Neutrophil-derived IL-1\u03b2 impairs the efficacy of NF-\u03baB inhibitors against lung cancer. Cell Rep. 16, 120\u2013132 (2016).","journal-title":"Cell Rep."},{"key":"1131_CR187","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR188","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833\u20131842 (2017).","journal-title":"Lancet"},{"key":"1131_CR189","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.jtho.2023.09.134","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. MA03.10 The interim analysis of Can-Prevent-Lung Trial: canakinumab for the prevention of lung cancer. J. Thorac. Oncol. 18, S108\u2013S109 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR190","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012).","journal-title":"Nature"},{"key":"1131_CR191","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrc.2017.69","volume":"17","author":"CC Maley","year":"2017","unstructured":"Maley, C. C. et al. Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 17, 605\u2013619 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR192","first-page":"4243","volume":"24","author":"J Mattern","year":"2004","unstructured":"Mattern, J. & Volm, M. Imbalance of cell proliferation and apoptosis during progression of lung carcinomas. Anticancer Res. 24, 4243\u20134246 (2004).","journal-title":"Anticancer Res."},{"key":"1131_CR193","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1131_CR194","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2217\/fon-2020-1098","volume":"17","author":"P Garrido","year":"2021","unstructured":"Garrido, P. et al. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol. 17, 1459\u20131472 (2021).","journal-title":"Future Oncol."},{"key":"1131_CR195","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.23.00910","volume":"42","author":"EB Garon","year":"2024","unstructured":"Garon, E. B. et al. Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY \u2014 a double-blind, randomized clinical trial. J. Clin. Oncol. 42, 180\u2013191 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"L Paz-Ares","year":"2024","unstructured":"Paz-Ares, L. et al. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): a multicenter, randomized, double-blind, phase 3 trial. Lung Cancer 189, 107451 (2024).","journal-title":"Lung Cancer"},{"key":"1131_CR197","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.23.00980","volume":"42","author":"DSW Tan","year":"2024","unstructured":"Tan, D. S. W. et al. Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial. J. Clin. Oncol. 42, 192\u2013204 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1131_CR198","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/j.jtho.2025.09.507","volume":"20","author":"JJ Zhang","year":"2025","unstructured":"Zhang, J. J. et al. P2.02.36 Canakinumab interception trial and preclinical studies reveal stage-dependent biology in lung cancer and precancers. J. Thorac. Oncol. 20, S270\u2013S271 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn0327","volume":"386","author":"MD Park","year":"2024","unstructured":"Park, M. D. et al. Hematopoietic aging promotes cancer by fueling IL-1\u03b1-driven emergency myelopoiesis. Science 386, eadn0327 (2024).","journal-title":"Science"},{"key":"1131_CR200","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","volume":"22","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat. Rev. Clin. Oncol. 22, 200\u2013214 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR201","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ccell.2025.04.003","volume":"43","author":"B Zhu","year":"2025","unstructured":"Zhu, B. et al. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43, 1125\u20131140.e1110 (2025).","journal-title":"Cancer Cell"},{"key":"1131_CR202","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-17-1605","volume":"77","author":"S Sivakumar","year":"2017","unstructured":"Sivakumar, S. et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res. 77, 6119\u20136130 (2017).","journal-title":"Cancer Res."},{"key":"1131_CR203","doi-asserted-by":"publisher","first-page":"S587","DOI":"10.1016\/j.jtho.2025.09.1108","volume":"20","author":"JJ Zhang","year":"2025","unstructured":"Zhang, J. J. et al. PT1.01.03 IMPRINT-Lung: single-arm, multi-center phase II trial of immunotherapy with pembrolizumab for interception of high-risk lung nodules. J. Thorac. Oncol. 20, S587 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1131_CR204","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"1131_CR205","first-page":"645","volume":"97","author":"World Health Organization.","year":"2022","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. WHO 97 645\u2013672 (2022).","journal-title":"WHO"},{"key":"1131_CR206","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/0115680096360059250131075456","volume":"25","author":"MS Hussain","year":"2025","unstructured":"Hussain, M. S., Sultana, A., Bisht, A. S. & Gupta, G. Groundbreaking mRNA lung cancer vaccine trials: a new dawn in cancer treatment. Curr. Cancer Drug. Targets 25, 962\u2013967 (2025).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"1131_CR207","unstructured":"LungVax. University of Oxford, Department of Oncology https:\/\/www.oncology.ox.ac.uk\/research\/clinical-trials\/oncology-clinical-trials-office-octo\/prospective-trials\/lungvax (2025)."},{"key":"1131_CR208","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/jcm8040529","volume":"8","author":"R Chalela","year":"2019","unstructured":"Chalela, R. et al. EGFR and KRAS mutations in the non-tumoral lung. prognosis in patients with adenocarcinoma. J. Clin. Med. 8, 529 (2019).","journal-title":"J. Clin. Med."},{"key":"1131_CR209","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ajco.14042","volume":"21","author":"X Liang","year":"2025","unstructured":"Liang, X., Zhang, C. & Ye, X. Overdiagnosis and overtreatment of ground-glass nodule-like lung cancer. Asia Pac. J. Clin. Oncol. 21, 108\u2013114 (2025).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"1131_CR210","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2147\/CMAR.S147312","volume":"9","author":"NH Geessink","year":"2017","unstructured":"Geessink, N. H., Schoon, Y., Olde Rikkert, M. G. & van Goor, H. Training surgeons in shared decision-making with cancer patients aged 65 years and older: a pilot study. Cancer Manag. Res. 9, 591\u2013600 (2017).","journal-title":"Cancer Manag. Res."},{"key":"1131_CR211","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. & Rockwood, K. Frailty in older adults. N. Engl. J. Med. 391, 538\u2013548 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1131_CR212","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.chest.2018.03.021","volume":"153","author":"PJ Mazzone","year":"2018","unstructured":"Mazzone, P. J. COUNTERPOINT: should lung cancer screening be expanded to persons who don\u2019t currently meet accepted criteria set forth by the chest guidelines on lung cancer screening? no. Chest 153, 1303\u20131305 (2018).","journal-title":"Chest"},{"key":"1131_CR213","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.chest.2018.03.017","volume":"153","author":"DE Wood","year":"2018","unstructured":"Wood, D. E. POINT: should lung cancer screening be expanded to persons who don\u2019t currently meet accepted criteria set forth by the chest guidelines on lung cancer screening? yes. Chest 153, 1299\u20131302 (2018).","journal-title":"Chest"},{"key":"1131_CR214","doi-asserted-by":"crossref","unstructured":"Dubinett, S. M. Inflammation and Lung Cancer (Springer, 2015).","DOI":"10.1007\/978-1-4939-2724-1"},{"key":"1131_CR215","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"The Cancer Genome Atlas Research Network","year":"2012","unstructured":"The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u2013525 (2012).","journal-title":"Nature"},{"key":"1131_CR216","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550 (2014).","journal-title":"Nature"},{"key":"1131_CR217","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","volume":"150","author":"R Govindan","year":"2012","unstructured":"Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121\u20131134 (2012).","journal-title":"Cell"},{"key":"1131_CR218","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1256930","volume":"346","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256\u2013259 (2014).","journal-title":"Science"},{"key":"1131_CR219","doi-asserted-by":"publisher","first-page":"21994","DOI":"10.18632\/oncotarget.15777","volume":"8","author":"K Quek","year":"2017","unstructured":"Quek, K. et al. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8, 21994\u201322002 (2017).","journal-title":"Oncotarget"},{"key":"1131_CR220","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41379-018-0029-3","volume":"31","author":"WC Lee","year":"2018","unstructured":"Lee, W. C. et al. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod. Pathol. 31, 947\u2013955 (2018).","journal-title":"Mod. Pathol."},{"key":"1131_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02175-0","volume":"21","author":"WC Lee","year":"2020","unstructured":"Lee, W. C. et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 21, 271 (2020).","journal-title":"Genome Biol."},{"key":"1131_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05327-w","volume":"9","author":"J Nong","year":"2018","unstructured":"Nong, J. et al. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat. Commun. 9, 3114 (2018).","journal-title":"Nat. Commun."},{"key":"1131_CR223","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","volume":"24","author":"X Le","year":"2018","unstructured":"Le, X. et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin. Cancer Res. 24, 6195\u20136203 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR224","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41388-019-1104-z","volume":"39","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39, 1846\u20131859 (2020).","journal-title":"Oncogene"},{"key":"1131_CR225","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/1078-0432.CCR-20-1767","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. Clin. Cancer Res. 26, 5477\u20135486 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR226","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"1131_CR227","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1158\/2159-8290.CD-20-1559","volume":"11","author":"C Bailey","year":"2021","unstructured":"Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916\u2013932 (2021).","journal-title":"Cancer Discov."},{"key":"1131_CR228","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525\u2013533 (2023).","journal-title":"Nature"},{"key":"1131_CR229","doi-asserted-by":"publisher","first-page":"a041385","DOI":"10.1101\/cshperspect.a041385","volume":"14","author":"A Vaishnavi","year":"2024","unstructured":"Vaishnavi, A., Kinsey, C. G. & McMahon, M. Preclinical modeling of pathway-targeted therapy of human lung cancer in the mouse. Cold Spring Harb. Perspect. Med. 14, a041385 (2024).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1131_CR230","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler, I. J. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat. Rev. Cancer 3, 453\u2013458 (2003).","journal-title":"Nat. Rev. Cancer"}],"updated-by":[{"DOI":"10.1038\/s41571-026-01140-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01131-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:02:43Z","timestamp":1777032163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01131-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":230,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01131-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"6 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-026-01140-3","URL":"https:\/\/doi.org\/10.1038\/s41571-026-01140-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Z. has acted as a consultant and\/or adviser or speaker or received research funding from AstraZeneca, Beigene, Bicara, Bristol Myers Squibb, Catalyst, GenePlus, Helius, Hengrui, Innovent Biologics, Johnson & Johnson, Merck, Novartis, OrigMed, Oncohost, Roche, Summit, Takeda and Varian. T.P. has acted as a consultant for FutureHouse, Edison Scientific and Scale AI; and is listed as an inventor\u00a0(alongside C.S.) on patents filed in the UK related to\u00a0risk prediction and early detection of lung cancer that have been filed, but are\u00a0currently unpublished and remain within the priority year. E.S. has acted as an advisory board member or consultant for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Janssen and Regeneron; and works in an institution that received research funding from AstraZeneca and Delfi Diagnostics. T.U.M. has acted as an advisory and\/or data safety monitoring board member for AbbVie, AN2 Therapeutics, Arcus, Arrowhead, Astellas, AstraZeneca, Avammune, DBV Technologies, EMD Serono, EvolveImmune, Fate, G1 Therapeutics, Geneos, Genentech, Glenmark, Merck, Natures Toolbox, NGMbio, Ono Pharmaceutical, Regeneron, Replimmune, Storm and Tubulis; has received research grants from Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Merck and Regeneron; and holds stock options in Natures Toolbox. J.V.H. reports honoraria from AstraZeneca, Boehringer Ingelheim, BMS, BrightPath Biotherapeutics, Catalyst, Eli Lilly, EMD Serono, Foundation Medicine,Genentech, GSK, Guardant Health, Hengrui Therapeutics, Janssen, Kairos Venture Investments, Leads Biolanbs, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche, Sanofi, Spectrum and Takeda. S.M.D. has been on the scientific advisory boards for EarlyDiagnostics and LungLife AI, Inc. P.-C.Y. has acted as a consultant and\/or adviser or speaker or received research funding from ACT Genomics, AstraZeneca, Boehringer Ingelheim, CHO Pharma, DELTA Electronics, Eli Lilly, GSK, Merck, MSD, OBI Pharma, Onenessbio, Ono Pharmaceutical, Pfizer, and Roche. C.S. has received grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Invitae (previously Archer Dx Inc.), Ono Pharmaceutical, Personalis, Pfizer and Roche\u2013Ventana; is Chief Investigator and Steering Committee Chair for the AstraZeneca MeRmaiD 1 and 2 clinical trials; is Co-Chief Investigator of the NHS Galleri trial funded by GRAIL; has received consultant fees from Achilles Therapeutics, Bicycle Therapeutics, China Innovation Centre of Roche (formerly Roche Innovation Centre, Shanghai), Genentech, Medicxi, Metabomed and the Sarah Cannon Research Institute; is a scientific advisory board member for Achilles Therapeutics, Bicycle Therapeutics, GRAIL, Relay Therapeutics and Saga Diagnostics; has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GSKline, Illumina, MSD, Novartis, Pfizer and Roche\u2013Ventana; has previously held stock options in Apogen Biotechnologies and GRAIL; currently has stock options in Achilles Therapeutics, Bicycle Therapeutics, Epic Bioscience and Relay Therapeutics; is co-founder of Achilles Therapeutics; is listed as an inventor in patent applications for methods to detect lung cancer (PCT\/US2017\/028013), targeting neoantigens (PCT\/EP2016\/059401), identifying patient response to immune-checkpoint blockade (PCT\/EP2016\/071471), methods for lung cancer detection (US20190106751A1), identifying patients with responses to cancer treatment (PCT\/GB2018\/051912), determining HLA loss of heterozygosity (PCT\/GB2018\/052004), predicting survival rates of patients with cancer (PCT\/GB2020\/050221), and methods and systems for tumour monitoring (PCT\/EP2022\/077987); is listed as an inventor on a European patent application (PCT\/GB2017\/053289) relating to assay technology to detect tumour recurrence that has been licensed to a commercial entity and under their terms of employment, and is due a revenue share of any revenue generated from such license(s). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}